Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Chandrima Sanyal

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Diet,And,Dieting.,Beauty,Slim,Female,Body,Use,Tape,Measure.

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far less calorie-dense ways to play the trend.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.